Working… Menu

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03552380
Recruitment Status : Recruiting
First Posted : June 11, 2018
Last Update Posted : September 16, 2019
Bristol-Myers Squibb
Syndax Pharmaceuticals
Indiana University School of Medicine
Information provided by (Responsible Party):
Roberto Pili, Hoosier Cancer Research Network

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2021